Is it financially beneficial for hospitals to prevent nosocomial infections?
Open Access
- 14 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Health Services Research
- Vol. 20 (1), 1-9
- https://doi.org/10.1186/s12913-020-05428-7
Abstract
BackgroundFinancial incentives represent a potential mechanism to encourage infection prevention by hospitals. In order to characterize the place of financial incentives, we investigated resource utilization and cost associated with hospital-acquired infections (HAI) and assessed the relative financial burden for hospital and insurer according to reimbursement policies.MethodsWe conducted a prospective matched case-control study over 18months in a tertiary university medical center. Patients with central-line associated blood-stream infections (CLABSI), Clostridium difficile infection (CDI) or surgical site infections (SSI) were each matched to three control patients. Resource utilization, costs and reimbursement (per diem for CLABSI and CDI, diagnosis related group (DRG) reimbursement for SSI) were compared between patients and controls, from both the hospital and insurer perspective.ResultsHAIs were associated with increased resource consumption (more blood tests, imaging, antibiotic days, hospital days etc.). Direct costs were higher for cases vs. controls (CLABSI: $6400 vs. $2376 (p<0.001), CDI: $1357 vs $733 (p=0.047) and SSI: $6761 vs. $5860 (p< 0.001)). However as admissions were longer following CLABSI and CDI, costs per-day were non-significantly different (USD/day, cases vs. controls: CLABSI, 601 vs. 719, (p=0.63); CDI, 101 vs. 93 (p=0.5)). For CLABSI and CDI, reimbursement was per-diem and thus the financial burden ($14,608 and $5430 respectively) rested on the insurer, not the hospital. For SSI, as reimbursement was per procedure, costs rested primarily on the hospital rather than the insurer.ConclusionNosocomial infections are associated with both increased resource utilization and increased length of stay. Reimbursement strategy (per diem vs DRG) is the principal parameter affecting financial incentives to prevent hospital acquired infections and depends on the payer perspective. In the Israeli health care system, financial incentives are unlikely to represent a significant consideration in the prevention of CLABSI and CDI.Funding Information
- Israel National Institute for Health Policy Research (NA)
This publication has 23 references indexed in Scilit:
- Effect of Nonpayment for Preventable Infections in U.S. HospitalsThe New England Journal of Medicine, 2012
- WINPEPI updated: computer programs for epidemiologists, and their teaching potentialEpidemiologic Perspectives & Innovations, 2011
- Costs Attributable to Healthcare-Acquired Infection in Hospitalized Adults and a Comparison of Economic MethodsMedical Care, 2010
- Economic burden of healthcare-associated infections: an American perspectiveExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- A Prospective Study of Outcomes, Healthcare Resource Utilization, and Costs Associated With Postoperative Nosocomial InfectionsInfection Control & Hospital Epidemiology, 2006
- Systematic review of economic analyses of health care-associated infectionsAmerican Journal of Infection Control, 2005
- Use of Maximal Sterile Barriers during Central Venous Catheter Insertion: Clinical and Economic OutcomesClinical Infectious Diseases, 2004
- The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysisAmerican Journal of Infection Control, 2003
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJAMA, 1993
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987